Active Ingredient(s): Elexacaftor + Ivacaftor + Tezacaftor
FDA Approved: * October 21, 2019
Pharm Company: * VERTEX PHARMS INC
Category: Genetic Disorders

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Trikafta Overview

Elexacaftor/tezacaftor/ivacaftor, sold under the brand names Trikafta (US) and Kaftrio (Europe), is a fixed-dose combination medication used with adults and children older than age 6 that have cystic fibrosis with a f508del mutation or other mutations.[5] Patients with cystic fibrosis have thicker mucus secretions due to genetic mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) protein which inhibits the transfer of chloride and sodium ions from cells...

Read more Trikafta Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source:

Recent Trikafta Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Elexacaftor + Ivacaftor + Tezacaftor
  • Tablet: 100mg,75mg,50mg + 150mg, 50mg,37.5mg,25mg + 75mg
  • Tablet, Tablet: 100mg,75mg,50mg + N/a,150mg,n/a
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Trikafta: (2 results)

Sorted by National Drug Code
  • 51167-106 TrikaftaTrikafta Kit by Vertex Pharmaceuticals Incorporated
  • 51167-331 TrikaftaTrikafta Kit by Vertex Pharmaceuticals Incorporated

Drugs with one or more similar ingredients: (7 results)